Connect with us


DiCE scores $80M to roll oral IL-17 psoriasis med into the clinic

Ovidiu Balaban-Popa



DiCE Molecules is setting its sights on the clinic. With $80 million raised from a laundry list of investors led by RA Capital Management, the company will push its lead program, an interleukin-17 (IL-17) antagonist, into a clinical trial in psoriasis and build out its preclinical programs.

“This financing will enable us to accelerate our lead IL-17 program through important milestones while advancing our other assets, including a pair of integrin inhibitors, and also to expand our pipeline using the same combination of technology and structural insights,” said DiCE CEO Kevin Judice, Ph.D., in a statement. “We believe the immunology space is underserved by current small molecule approaches and we are excited about the opportunity to advance next-generation therapeutics for this patient population.”

RELATED: Sanofi is rolling the DiCE on a small molecule R&D platform

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

DiCE’s pipeline is based on its DNA-encoded library (DEL) technology, which generates small molecules that target protein-protein interactions, which have long been difficult to drug.

Its lead program targets IL-17, a family of inflammation-promoting cytokines that play a role in psoriasis, psoriatic arthritis and other autoimmune diseases. Several drugs targeting IL-17A are already on the market, including Novartis’ Cosentyx, Eli Lilly’s Taltz and Bausch Health’s Siliq. But all three are monoclonal antibodies given by injection, and DiCE hopes to one-up them with an oral small molecule. UCB is working on an antibody that targets IL-17A and IL-17F, but it, too, is injected.

The series C funding, drawn from the likes of Alexandria Venture Investments, Sanofi Ventures and Osage University Partners, will also advance and expand DiCE’s preclinical work.

RELATED: Koller’s insitro snaps up Haystack to build up machine learning tech

Besides its in-house pipeline of immunology programs, DiCE is working with Sanofi on an immuno-oncology candidate. It has also teamed up with insitro to combine machine learning with its DEL capabilities.